Radiopharmaceutical firm Telix touts $151M in Q1 sales from PET imaging agent Illuccix

Australia-based radiopharmaceutical firm Telix announced its first quarter earnings results on Tuesday, touting $151 million (USD) in sales from its PET imaging agent Illuccix.

The product is used to help radiologists and other physicians identify and visualize prostate cancer cells, along with selecting candidates for PSMA (prostate-specific membrane antigen)-directed radiogland therapy. Telix said the nine-digit figure represents a 35% year-over-year increase compared to Q1 of 2024 and 9% uptick from the previous three months. 

“Illuccix has continued its momentum, gaining market share and maintaining price stability in a competitive landscape,” Christian Behrenbruch, PhD, MBA, managing director and group CEO at Telix, said in a statement April 22. “The expansion of our commercial portfolio and launches of Illuccix into new international markets provides a foundation to diversify and grow revenue globally, while we continue to deliver on multiple catalysts in our pipeline,” he added later. 

The U.S. Food and Drug Administration first approved the imaging agent in late 2021, following in the footsteps of the first commercially available PSMA PET imaging agent, Pylarify. Both have seen tremendous interest amid rising PET imaging volumes, with Pylarify recording some $1 billion in sales last year. Tellix, meanwhile, generated $783.2 million in 2024 revenues, primarily driven by sales of Illuccix. 

Behrenbruch said Tellix is currently the only company with two U.S. Food and Drug Administration-approved, PSMA-PET imaging agents. Last month, it also scored the agency’s blessing for Gozellix, which has a longer shelf life of up to six hours. This paves the way for increased access to clinics where prostate PET imaging may not have been available in the past. Gozellix also allows for scalable production and more flexible scheduling, the company said last month. 

Leaders on Tuesday also discussed Tellix’s recent acquisition of RLS for $250 million. The firm operates America’s only Joint Commission-accredited radiopharmacy network, with 31 locations covering over 85% of the U.S. population. Headquartered in Lake Mary, Florida, RLS distributes PET and SPECT agents along with therapeutic radiopharmaceuticals, serving over 1,500 customers. Telix has now collected about $33 million from RLS since the transaction closed. 

“This quarter also includes the first two months of revenue from RLS since completion of our acquisition, highlighting its potential as a platform to drive further growth,” Behrenbruch said in the announcement. “This strategic acquisition has significantly expanded our manufacturing footprint in the U.S., which we believe is an increasingly important consideration amid changing global trade dynamics.”

Telix also continues to seek approvals for additional imaging agents including Zircaix for kidney cancer and Pixclara for brain cancer. The company said in February that it expects to record revenue at upward of $800 million in 2025, with Illuccix the primary driver.